Andersons pediatric cardiology 2116
Bạn đang xem bản rút gọn của tài liệu. Xem và tải ngay bản đầy đủ của tài liệu tại đây (60.11 KB, 3 trang )
ofmetabolizingenzymesinvolvedwith
glucuronidation(UGT).Theauthorsdescribe
theclassofenzymeswhilesimultaneously
highlightingexisitngevidenceandknowledge
gapsofUGTpharmacogeneticsandontogeny..
PrasadB,GaedigkA,VranaM,etal.Ontogenyof
hepaticdrugtransportersasquantifiedbyLCMS/MSproteomics.ClinPharmacolTher.
2016;100(4):362–370.
Thiscomprehensiveproteomicanalysisina
pediatriclivercohortdescribestheontogeny
patternofhepaticuptakeandeffluxtransporters
relevantdrugdiposition.Thisworkdescribesthe
ontogenypatternthatcanbeleveragedtoinform
physiologicallybasedpharmacokinetic(PBPK)
modelsthatcanpredicthepaticdrugexposurein
childrenandadolescents..
HoRH,KimRB.Transportersanddrugtherapy:
implicationsfordrugdispositionanddisease.
ClinPharmacolTher.2005;78(3):260–277.
Thiscomprehensivereviewfromtwoworldexperts
indrugtransportersdescribesthedrug
transportersrelevanttocurrentdrugdisposition
anddisease..
InternationalWarfarinPharmacogenetics
Consortium,KleinTE,AltmanRB,etal.
Estimationofthewarfarindosewithclinicaland
pharmacogeneticdata.NEnglJMed.
2009;360(8):753–764.
Thisconsortiumdescribesthepharmacogenetic
algorithmtoimprovepredictionsofappropriate
warfarindosingcomparedtotrasditionalfixeddoseapproach..
ScottSA,SangkuhlK,SteinCM,etal.Clinical
pharmacogeneticsimplementationconsortium
guidelinesforCYP2C19genotypeand
clopidogreltherapy:2013update.Clin
PharmacolTher.2013;94(3):317–323.
Thisconsortiumdescribestheupdatedevidence
andguidelinesforCYP2C19genotype-based
clopidogreldosing..
RamseyLB,JohnsonSG,CaudleKE,etal.The
clinicalpharmacogeneticsimplementation
consortiumguidelineforSLCO1B1and
simvastatin-inducedmyopathy:2014update.
ClinPharmacolTher.2014;96(4):423–428.
Thisconsortiumdescribestheupdatedevidence
andguidelinesforSLCO1B1genotype-based
simvastatindosing..
VanDriestSL,WebberSA.Pharmacogenomics:
personalizingpediatrichearttransplantation.
Circulation.2015;131(5):503–512.
Thispivotalreviewbyawellknownpediatric
clinicalpharmacologistandpediatrictransplant
cardiologisthighlightsthecurrent
pharmacogenomicevidencerelatedtocardiac
transplantationandopportunitiesforfuture
researchandclinicalcare..
BirdwellKA,DeckerB,BarbarinoJM,etal.
Clinicalpharmacogeneticsimplementation
consortium(CPIC)guidelinesforCYP3A5
genotypeandtacrolimusdosing.ClinPharmacol
Ther.2015;98(1):19–24.
Thisconsortiumdescribestheupdatedevidence
andguidelinesforCYP3A5genotype-based
tacrolimusdosing..
Abdel-RahmanSM,BreitkreutzML,BiC,etal.
DesignandtestingofanEHR-integrated,
Busulfanpharmacokineticdecisionsupporttool
forthePoint-of-careclinician.FrontPharmacol.
2016;7:65.
Thisinovativeresearchdescribesaprovider
decisionsupporttoolthatisutilizedtoprecisely
dosepediatricbusulfaninbonemarrow
transplantrecipients..
